Effect of Curcuma xanthorrhiza Supplementation on Systemic Lupus Erythematosus Patients with Hypovitamin D Which Were Given Vitamin D3 towards Disease Activity (SLEDAI), IL-6, and TGF- β 1 Serum

C Singgih Wahono, Cameleia Diah Setyorini, Handono Kalim, Nurdiana Nurdiana, Kusworini Handono, C Singgih Wahono, Cameleia Diah Setyorini, Handono Kalim, Nurdiana Nurdiana, Kusworini Handono

Abstract

Background: Curcumin contained in Curcuma xanthorrhiza is an immunomodulator that has similar biological effect as vitamin D. Combination of curcumin and vitamin D3 is expected to work synergistically.

Objective: To determine the effect of Curcuma xanthorrhiza supplementation on vitamin D3 administration to SLEDAI, IL-6, and TGF-β1 serum in SLE patients with hypovitamin D.

Methods: This was a double-blind RCT conducted in Saiful Anwar Hospital, Malang, in January 2016-March 2017. Subjects were SLE active (SLEDAI > 3) with levels of 25(OH)D3 ≤ 30 ng/ml and divided into two groups: those receiving cholecalciferol 3 × 400 IU and placebo 3 × 1 tablets (group I) and those receiving 3 × 400 IU cholecalciferol and Curcuma xanthorrhiza 3 × 20 mg for 3 months (group II). SLEDAI, levels of vitamin D, IL-6, and TGF-β1 in serum were evaluated before and after the treatment.

Results: There were no significant differences in SLEDAI reduction, decreased serum levels of IL-6, and increased levels of TGF-β1 serum among groups after the treatment. Decreased levels of serum IL-6 have a positive correlation with SLEDAI reduction. Conclusion. Curcuma xanthorrhiza supplementation on vitamin D3 had no effects on SLEDAI and serum levels of IL-6 and TGF-β1. This clinical trial is registered with NCT03155477.

Figures

Figure 1
Figure 1
Effects of Curcuma xanthorrhiza supplementation on vitamin D3 administration towards vitamin D level. ∗There is a significant difference (p < 0.005).
Figure 2
Figure 2
Effects of Curcuma xanthorrhiza supplementation on vitamin D3 administration towards SLEDAI. ∗There is a significant difference (p < 0.005).
Figure 3
Figure 3
Correlation between SLEDAI and decline of IL-6 serum after supplementation.
Figure 4
Figure 4
Correlation between SLEDAI and elevation of TGF-β1 serum after supplementation.

References

    1. IRA. Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. 2011.
    1. Shah K., Lee W., Lee S., et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Research & Therapy. 2010;12(2) doi: 10.1186/ar2964.
    1. Dolff S., Bijl M., Huitema M. G., Limburg P. C., Kallenberg C. G. M., Abdulahad W. H. Disturbed Th1, Th2, Th17 and Treg balance in patients with systemic lupus erythematosus. Clinical Immunology. 2011;141(2):197–204. doi: 10.1016/j.clim.2011.08.005.
    1. Ruiz-Irastorza G., Egurbide M. V., Olivares N., Martinez-Berriotxoa A., Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: Prevalence, predictors and clinical consequences. Rheumatology. 2008;47(6):920–923. doi: 10.1093/rheumatology/ken121.
    1. Ruiz-Irastorza G., Gordo S., Olivares N., Egurbide M.-V., Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. Arthritis Care & Research. 2010;62(8):1160–1165. doi: 10.1002/acr.20186.
    1. Puspitasari L., Kalim H., Rudijanto A., Wahono C. S. Korelasi kadar vitamin D serum dengan aktivitas penyakit pasien Lupus Eritematosus Sistemik (SLEDAI) Malang, Indonesia: Universitas Brawijaya; 2012.
    1. Toloza S. M. A., Cole D. E. C., Gladman D. D., Ibañez D., Urowitz M. B. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010;19(1):13–19. doi: 10.1177/0961203309345775.
    1. O'Leary T. J., Jones G., Yip A., Lohnes D., Cohanim M., Yendt E. R. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. The New England Journal of Medicine. 1986;315(12):727–730. doi: 10.1056/NEJM198609183151203.
    1. Carvalho J. F., Blank M., Kiss E., Tarr T., Amital H., Shoenfeld Y. Anti-vitamin D, vitamin D in SLE: preliminary results. Annals of the New York Academy of Sciences. 2007;1109:550–557. doi: 10.1196/annals.1398.061.
    1. Handono K., Hasanah D., Kalim H., Mawarti H. The association among serum levels of vitamin D, TGf-ß/IL-6 balance and Treg/Th17 balance in systemic lupus erythematosus patients in Indonesia. International Journal of Biochemistry and Biotechnology. 2013;2:490–496.
    1. Rifai A., Wahono CS., Kalim H. The effect of Vitamin D3 supplementation toward disease activity and fatigue in SLE patients with hypovitamin D. Malang, Indonesia: Brawijaya University; 2014.
    1. Barreto M., Ferreira R. C., Lourenço L., et al. Low frequency of CD4+CD25+ Treg in SLE patients: A Heritable trait associated with CTLA4 and TGFβ gene variants. BMC Immunology. 2009;10(1) doi: 10.1186/1471-2172-10-5.
    1. Bright J. J. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. Springer; 2007. Curcumin and autoimmune disease; pp. 425–451.
    1. Haussler M. R., Haussler C. A., Bartik L., et al. Vitamin D receptor: Molecular signaling and actions of nutritional ligands in disease prevention. Nutrition Reviews. 2008;66(2):S98–S112. doi: 10.1111/j.1753-4887.2008.00093.x.
    1. Bartik L., Whitfield G. K., Kaczmarska M., et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. The Journal of Nutritional Biochemistry. 2010;21(12):1153–1161. doi: 10.1016/j.jnutbio.2009.09.012.
    1. Pratama M. Z., Wahono C. S., Handono K., et al. Immune supression effects of curcumin in pristane induced lupus mice. International Journal of Rheumatic Disease. 2015
    1. Khajehdehi P., Zanjaninejad B., Aflaki E., et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. Journal of Renal Nutrition. 2012;22(1):50–57. doi: 10.1053/j.jrn.2011.03.002.
    1. Ross A. C., Taylor C. L., Yaktine A. L., Del Valle H. B. Food and Nutrition Board. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC, USA: National Academy Press; 2011.
    1. Van Groningen L., Opdenoordt S., Van Sorge A., Telting D., Giesen A., De Boer H. Cholecalciferol loading dose guideline for vitamin D-deficient adults. European Journal of Endocrinology. 2010;162(4):805–811. doi: 10.1530/EJE-09-0932.
    1. NHS. Guidelines for the Prescribing of Vitamin D in Adults. 2013.
    1. Cannell J. J., Hollis B. W., Zasloff M., Heaney R. P. Diagnosis and treatment of vitamin D deficiency. Expert Opinion on Pharmacotherapy. 2008;9(1):107–118. doi: 10.1517/14656566.9.1.107.
    1. Abou-Raya A., Abou-Raya S., Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. The Journal of Rheumatology. 2013;40(3):265–272. doi: 10.3899/jrheum.111594.
    1. Petri M., Bello K. J., Fang H., Magder L. S. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis & Rheumatology. 2013;65(7):1865–1871. doi: 10.1002/art.37953.
    1. Karimzadeh H., Shirzadi M., Karimifar M. The effect of Vitamin D supplementation in disease activity of systemic lupus erythematosus patients with Vitamin D deficiency: A randomized clinical trial. Journal of Research in Medical Sciences. 2017;22(1) doi: 10.4103/1735-1995.199089.
    1. Spronk P. E., Borg E. J., LImburgf P. C., Kallenberg C. G. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clinical & Experimental Immunology. 1992;90(1):106–110. doi: 10.1111/j.1365-2249.1992.tb05840.x.
    1. Cytokines and Systemic Lupus Erythematosus, .
    1. Nonn L., Peng L., Feldman D., Peehl D. M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Research. 2006;66(8):4516–4524. doi: 10.1158/0008-5472.can-05-3796.
    1. Non L., Duong D., Peehl D. M. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis. 2007;28(6):1188–1196. doi: 10.1093/carcin/bgl241.
    1. Jäger R., Lowery R. P., Calvanese A. V., Joy J. M., Purpura M., Wilson J. M. Comparative absorption of curcumin formulations. Nutrition Journal . 2014;13, article 11 doi: 10.1186/1475-2891-13-11.
    1. Aggarwal B. B., Surh Y.-J., Shishodia S. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. Vol. 595. Springer Science & Business Media; 2007.
    1. Menegaz D., Mizwicki M. T., Barrientos-Duran A., Chen N., Henry H. L., Norman A. W. Vitamin d receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP) Molecular Endocrinology. 2011;25(8):1289–1300. doi: 10.1210/me.2010-0442.
    1. Guo C., Rosoha E., Lowry M. B., Borregaard N., Gombart A. F. Curcumin induces human cathelicidin antimicrobial peptide gene expression through a vitamin D receptor-independent pathway. The Journal of Nutritional Biochemistry. 2013;24(5):754–759. doi: 10.1016/j.jnutbio.2012.04.002.
    1. Anand P., Kunnumakkara A. B., Newman R. A., Aggarwal B. B. Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics. 2007;4(6):807–818. doi: 10.1021/mp700113r.
    1. Jacob A., Wu R., Zhou M., Wang P. Mechanism of the anti-inflammatory effect of curcumin: PPAR-γ activation. PPAR Research. 2007;2007:5. doi: 10.1155/2007/89369.89369
    1. Narala V. R., Smith M. R., Adapala R. K., et al. Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ. Gene therapy & molecular biology. 2009;13(1):20–25.
    1. Adhya Z., Borozdenkova S., Karim M. Y. The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis. Nephrology Dialysis Transplantation . 2011;26(10):3273–3280. doi: 10.1093/ndt/gfq860.
    1. Ohtsuka K., Gray J. D., Stimmler M. M., Toro B., Horwitz D. A. Decreased production of TGF-β by lymphocytes from patients with systemic lupus erythematosus. The Journal of Immunology. 1998;160(5):2539–2545.
    1. Mo N., Li Z.-Q., Li J., Cao Y.-D. Curcumin inhibits TGF-beta1-induced MMP-9 and invasion through ERK and smad signaling in breast cancer MDA-MB-231 cells. Asian Pacific Journal of Cancer Prevention. 2012;13(11):5709–5714. doi: 10.7314/apjcp.2012.13.11.5709.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi